New! Search for patents from more than 100 countries including Australia, Brazil, Sweden and more

EP0938334A4 - Improved method of treating immune cell mediated systemic diseases - Google Patents

Improved method of treating immune cell mediated systemic diseases

Info

Publication number
EP0938334A4
EP0938334A4 EP97936109A EP97936109A EP0938334A4 EP 0938334 A4 EP0938334 A4 EP 0938334A4 EP 97936109 A EP97936109 A EP 97936109A EP 97936109 A EP97936109 A EP 97936109A EP 0938334 A4 EP0938334 A4 EP 0938334A4
Authority
EP
European Patent Office
Prior art keywords
improved method
immune cell
cell mediated
systemic diseases
treating immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97936109A
Other languages
German (de)
French (fr)
Other versions
EP0938334A1 (en
Inventor
Charles Baldwin Davis
Peter John Bugelski
Brian Richard Macdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US2247296P priority Critical
Priority to US22472P priority
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to PCT/US1997/012600 priority patent/WO1998004281A1/en
Publication of EP0938334A1 publication Critical patent/EP0938334A1/en
Publication of EP0938334A4 publication Critical patent/EP0938334A4/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
EP97936109A 1996-07-26 1997-07-25 Improved method of treating immune cell mediated systemic diseases Withdrawn EP0938334A4 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US2247296P true 1996-07-26 1996-07-26
US22472P 1996-07-26
PCT/US1997/012600 WO1998004281A1 (en) 1996-07-26 1997-07-25 Improved method of treating immune cell mediated systemic diseases

Publications (2)

Publication Number Publication Date
EP0938334A1 EP0938334A1 (en) 1999-09-01
EP0938334A4 true EP0938334A4 (en) 2004-12-15

Family

ID=21809771

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97936109A Withdrawn EP0938334A4 (en) 1996-07-26 1997-07-25 Improved method of treating immune cell mediated systemic diseases

Country Status (3)

Country Link
EP (1) EP0938334A4 (en)
JP (1) JP2000516594A (en)
WO (1) WO1998004281A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05483B1 (en) * 1998-12-23 2011-10-17 Pfizer, Inc. Anti-CTLA-4 human monoclonal antibodies
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
AU777970C (en) 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
MXPA03002262A (en) * 2000-09-18 2003-10-15 Idec Pharma Corp Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination.
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
ES2524694T3 (en) 2002-10-17 2014-12-11 Genmab A/S CD20 Human Monoclonal Antibodies Against
CA2525251C (en) 2003-05-09 2015-10-27 Duke University Cd20-specific antibodies and methods employing same
HUE031632T2 (en) 2003-11-05 2017-07-28 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
TWI556829B (en) 2004-04-09 2016-11-11 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating tnfα-related disorders
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
AT503187T (en) * 2004-12-23 2011-04-15 Hoffmann La Roche Detection of a therapeutic antibody in an experimental animal
CA2903138A1 (en) 2005-05-16 2006-11-23 Abbvie Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
US20070087029A1 (en) * 2005-10-14 2007-04-19 Pakala Syamasundar V Localized delivery to the lymphatic system
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2012022682A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
EP2788020A4 (en) 2011-12-05 2015-04-29 Immunomedics Inc Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
KR20150047140A (en) 2012-09-07 2015-05-04 코히러스 바이오사이언시즈, 인코포레이티드 Stable aqueous formulations of adalimumab
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9028833B2 (en) 2012-12-13 2015-05-12 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
WO2015130416A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009351A1 (en) * 1995-09-06 1997-03-13 Idec Pharmaceuticals Corporation Recombinant anti-cd4 antibodies for human therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126433A (en) * 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009351A1 (en) * 1995-09-06 1997-03-13 Idec Pharmaceuticals Corporation Recombinant anti-cd4 antibodies for human therapy

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BATA-CSORGO Z ET AL: "Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY. JUL 1995, vol. 105, no. 1 Suppl, July 1995 (1995-07-01), pages 89S - 94S, XP009034211, ISSN: 0022-202X *
EMMRICH F ET AL: "An anti-CD4 antibody for treatment of chronic inflammatory arthritis.", AGENTS AND ACTIONS. SUPPLEMENTS. 1991, vol. 32, 1991, pages 165 - 170, XP001182725, ISSN: 0379-0363 *
GAVETT S H ET AL: "Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia.", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY. JUN 1994, vol. 10, no. 6, June 1994 (1994-06-01), pages 587 - 593, XP009034204, ISSN: 1044-1549 *
KAINE J ET AL: "RESULTS OF A MULTI-DOSE PROTOCOL 7002 USING AN IMMUNOMODULATING NON-DEPLETING PRIMATIZEDTM ANTI-CD4 MONOCLONAL ANTIBODY IN RHEUMATOID ARTHRITIS (RA)", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 38, no. 9, SUPPL, 21 November 1995 (1995-11-21), pages S185,AN195, XP001095999, ISSN: 0004-3591 *
MORELAND L W ET AL: "TREATING RHEUMATOID ARTHRITIS WITH A NON-DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY", JOURNAL OF INVESTIGATIVE MEDICINE, AMERICAN FEDERATION FOR CLINICAL RESEARCH,, US, vol. 43, no. SUPPL 2, 5 May 1995 (1995-05-05), pages 362A, XP001106168, ISSN: 1081-5589 *
See also references of WO9804281A1 *
THIVOLET J ET AL: "Immunointervention in psoriasis with anti-CD4 antibodies.", INTERNATIONAL JOURNAL OF DERMATOLOGY. MAY 1994, vol. 33, no. 5, May 1994 (1994-05-01), pages 327 - 332, XP009034206, ISSN: 0011-9059 *
YOCUM D E ET AL: "CLINICAL AND IMMUNOPHARMACOLOGIC EFFECTS OF PRIMATIZEDTM IDEC-CE9.1, AN ANTI-CD4 MONOCLONALANTIBODY IN A PHASE I TRIAL IN ACTIVE RHEUMATOID ARTHRITIS", JOURNAL OF INVESTIGATIVE MEDICINE, AMERICAN FEDERATION FOR CLINICAL RESEARCH,, US, vol. 43, no. SUPPL 2, April 1995 (1995-04-01), pages 253A, XP001095992, ISSN: 1081-5589 *

Also Published As

Publication number Publication date
WO1998004281A1 (en) 1998-02-05
EP0938334A1 (en) 1999-09-01
JP2000516594A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
GB2319796B (en) Formation treatment method using deformable particles
US5827889A (en) Anal fissure treatment preparation and method
GB2255262B (en) Electric heater and method of making same
PL179271B1 (en) Method of obtaining 2-aminoalcanic acids
PL176853B1 (en) Method of obtaining epichlorohydine
EG20987A (en) Heat treatment of caron materials
EG22212A (en) Method of increasing foreign protein expression
GB2300656B (en) Edging means and method
FI97743B (en) Insulation and method of producing the same
GB2294880B (en) Method of treating turf
GB2359316B (en) Formation treatment method using deformable particles
GB2310815B (en) Surface covering and process for its manufacture
SU1514529A1 (en) Method of electric discharge alloying
PL182009B1 (en) Method of obtaining 3-isocyanate-propylsilane
EG20477A (en) Dual textured implement for personal cleasing and method of construction
KR0186327B1 (en) Method of fabricating mosfet
KR0186499B1 (en) Method of manufacturing anti-fuze
GB2311999B (en) Apparatus and method of electrodiaysis
GB2322663B (en) Walling method and apparatus
EG20725A (en) Method of treating fine ore
GB2318489B (en) Radiant electric heater and method of manufacture
GB2323507B (en) Electric heater unit and method of manufacture
RU2089619C1 (en) Method of treatment of slag-metal melt
AU4909397A (en) Method for improved stimulation treatment
KR0186540B1 (en) Electrode of pdp and its forming method

Legal Events

Date Code Title Description
AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

17P Request for examination filed

Effective date: 19990215

A4 Despatch of supplementary search report

Effective date: 20041022

18D Deemed to be withdrawn

Effective date: 20050111